Topical use of mitomycin C in laser myringotomy: an experimental study in rats.
OBJECTIVE
Ventilation tubes are used to a large extent for the treatment of otitis media with effusion. As this has some drawbacks, laser myringotomy was suggested as a treatment alternative. The use of laser has some advantages but its use is limited in prolonging the patency rate of myringotomy. Mitomycin C (MMC) is being used in some surgical applications to reduce stenosis as it has the property to inhibite activity of fibroblasts. We explored the use of mitomycin C as an adjunct in prolonging the patency rate in laser myringotomy on rats.


METHODS
We performed laser myringotomy on both ears of 20 rats. We, then applied MMC with a concentration of 2 mg/ml on 10 rats to one of their ears (Group 1). In group 2 we used MMC with a concentration of 1 mg/ml. After a follow-up of 8 weeks we calculated the patency rate for the two groups and the total ears with MMC and without MMC.


RESULTS
The mean patency rate observed for group 1 was found to be 6 weeks whereas for group 2, it was 5.8 weeks. The overall patency rate for the ears with and without MMC is 5.9 and 1.5 weeks, respectively. While there was a statistical difference between ears with and without MMC (P<0.01), there was no difference between the two groups according to concentrations.


CONCLUSIONS
Mitomycin C has an adjunct effect in laser myringotomy in prolonging the patency rate of myringotomy on rats. Low concentrations of mitomycin C have the same effect in this issue.
Yucel
O T
OT
ENT Department, Medical Faculty, Hacettepe University, Ankara, Turkey. tyucel@tr-net.net.tr
D000287:Administration, Topical; D000818:Animals; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D053685:Laser Therapy / Q000379:methods; D008297:Male; D008876:Middle Ear Ventilation / Q000379:methods*; D016685:Mitomycin / Q000008:administration & dosage*; D010034:Otitis Media with Effusion / Q000188:drug therapy* / Q000601:surgery*; D011183:Postoperative Complications / Q000517:prevention & control; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D016896:Treatment Outcome
D016685:Mitomycin